Lymphatic filariasis (LF), already recognized as a widespread, seriously ha
ndicapping disease of adults, was generally thought to occur only sporadica
lly in children. New, highly sensitive diagnostic tests (antigen detection,
ultrasound examination) now reveal, however, that LF is first acquired in
childhood, often with as many as one-third of children infected before age
5. Initial damage to the lymphatic system by the parasites generally remain
s subclinical for years or gives rise only to non-specific presentations of
adenitis/adenopathy; however, especially after puberty the characteristic
clinical features of the adult disease syndromes (lymphoedema, hydrocoele)
manifest themselves. Recognizing that LF disease starts its development in
childhood hag immediate practical implications both for management and prev
ention of the disease in individual patients and for the broader public hea
lth efforts to overcome all childhood illnesses. For the new World Health O
rganization (WHO) -supported, public-private-sector collaboration. (Global
Alliance) to eliminate LF through once-yearly drug treatment, this recognit
ion means that children will be not only the principal beneficiaries of LF
elimination but also a population particularly important to target in order
for the programme to achieve its twin goals of interrupting transmission a
nd preventing disease.